A new DEA registration pathway pulls state-licensed medical cannabis manufacturers, distributors, and labs into the federal Schedule III framework—potentially easing 280E tax pain.

Canopy Growth will supply four Canadian-grown flower strains to UK patients through GROW Group—an expansion with ripple effects for delivery, logistics, and investors across the European cannabis market.

The Nasdaq notice lifts delisting risk for IM Cannabis and spotlights how bid-price compliance can ripple across marijuana delivery stocks, founders, and DMV investors.

A private cannabis lender is advertising 17% yields to accredited investors while disclosing little. Here’s what New Cannabis Ventures found—and what DMV founders and investors should watch.

S&P added Trulieve to its Total Market and Completion indices. Here’s what that could mean for investors, delivery operators, and the DMV’s cannabis economy.

MJBizDaily reports Endovia is seeking FDA veterinary approval for a cannabinoid drug aimed at canine cancer and chronic pain—an R&D path that could reshape investor focus.

Vanguard’s move to acquire AI-forward custodian Altruist could reshape how investors access advice—and how cannabis entrepreneurs and investors navigate capital and delivery models.

Aurora told shareholders not to tender to Curaleaf’s hostile bid and signaled it’s weighing alternatives, sharpening focus on valuation, upside sharing, and voting control.